Overview
- Hims & Hers had its 2026 price target lowered to $21 with a Neutral rating, and the stock trades near $20 after a 39% slide this year.
- Bank of America now models 2026 operating profit about 20% below Wall Street’s view and expects GLP‑1 profit contribution to drop by up to 50% from last year.
- The company pivoted in March to FDA‑approved brands after a settlement with Novo Nordisk, a move that carries lower margins despite higher monthly prices.
- Bank of America estimates 40% to 50% of users could move to the $149 branded plan, producing $60 million to $90 million in quarterly GLP‑1 revenue while Eucalyptus initially cuts profit margin by 1 to 2 points.
- Competition tightened as Amazon Pharmacy began offering Eli Lilly’s new oral GLP‑1 drug Foundayo with same‑day delivery in nearly 3,000 cities, priced from $25 with insurance or $149 for cash pay.